util
diagnost
studi
determin
etiolog
agent
communityacquir
pneumonia
cap
controversi
part
lack
rapid
accur
easili
perform
costeffect
method
might
allow
result
patient
initi
point
servic
ie
initi
evalu
clinician
offic
acut
care
set
note
except
introduct
urinari
antigen
test
streptococcu
pneumonia
legionella
slow
advanc
diagnost
method
determin
etiolog
agent
cap
past
centuri
part
reli
techniqu
use
sinc
time
koch
pasteurstandard
microbiolog
stain
cultur
method
recent
advanc
molecular
test
method
brought
forth
new
potenti
diagnosi
rapid
identif
pathogen
possibl
addit
recent
studi
suggest
procalcitonin
level
help
distinguish
bacteri
viral
pneumonia
reduc
antibacteri
use
predict
sever
cap
articl
explor
new
diagnost
test
immunochromatograph
antigen
test
molecular
test
procalcitonin
assess
clinic
util
identif
etiolog
cap
recent
year
minim
result
random
clinic
trial
caus
cap
patient
admit
hospit
determin
approxim
case
observ
studi
rang
less
outpati
approxim
inpati
present
sever
issu
contribut
difficulti
establish
etiolog
diagnosi
pneumonia
includ
problem
current
avail
diagnost
test
recent
trend
toward
empir
therapi
without
emphasi
establish
etiolog
diagnosi
delay
outsourc
laboratori
test
tradit
cultur
method
detect
respiratori
tract
pathogen
slow
often
insensit
may
distinguish
infect
colon
may
influenc
previou
antibiot
therapi
result
diagnost
laboratori
test
may
requir
sever
day
cultur
identif
serolog
test
vitro
suscept
result
time
administr
antibiot
pivot
factor
recoveri
sever
infect
empir
therapi
becom
recogn
recommend
practic
cultur
sputum
minor
patient
expector
adequ
specimen
sputum
obtain
alway
problem
distinguish
colon
true
pathogen
past
sever
decad
broadspectrum
empir
therapi
becom
predomin
approach
manag
cap
studi
found
empir
therapi
given
result
diagnost
laboratori
test
affect
manag
spectrum
empir
agent
broad
regardless
whether
pathogen
identifi
clinic
respons
uniform
often
evid
time
laboratori
result
avail
physician
result
microbiolog
test
includ
sputum
cultur
gram
stain
even
blood
cultur
becam
deemphas
accord
recent
infecti
diseas
societi
americaamerican
thorac
societi
guidelin
microbiolog
test
present
univers
recommend
highrisk
patient
intens
care
unit
icu
admit
hospit
although
numer
reason
propos
decreas
microbiolog
test
power
influenc
far
rise
empiric
widespread
use
broadspectrum
empir
therapi
antimicrobi
resist
increas
addit
trend
toward
signific
declin
role
microbiolog
laboratori
hospit
set
mani
hospit
microbiolog
specimen
outsourc
health
care
facil
privat
laboratori
may
lead
delay
turnaround
time
decreas
commun
result
loss
specimen
viabil
addit
clinic
laboratori
improv
amend
requir
staff
credenti
interpret
gram
stain
virtual
elimin
hous
staff
attend
laboratori
locat
ward
recent
rapid
increas
technolog
innov
molecular
test
significantli
associ
use
nucleic
acid
amplif
test
naat
polymeras
chain
reaction
pcr
new
test
becom
avail
mark
expans
diagnost
capabl
infecti
diseas
newer
test
may
allow
rapid
etiolog
diagnosi
includ
newer
gener
immunochromatograph
urinari
antigen
test
well
naat
immunochromatograph
ict
test
detect
solubl
pneumococc
antigen
legionella
antigen
urin
import
advanc
diagnost
assess
pathogen
test
much
less
influenc
prior
antibiot
therapi
sputum
blood
cultur
eas
perform
ict
cardtyp
urin
test
make
ideal
use
emerg
depart
longterm
care
facil
even
physician
offic
although
present
waiv
food
drug
administr
fda
nonlaboratori
offic
use
ict
urinari
antigen
test
particularli
attract
detect
pneumococc
pneumonia
cultur
obtain
time
fashion
antibiot
therapi
alreadi
initi
serial
specimen
known
bacterem
case
pneumococc
urinari
antigen
detect
ict
assay
still
posit
case
day
therapi
form
urinari
antigen
test
princip
addit
advantag
rapid
minut
simplic
reason
specif
adult
studi
adult
shown
sensit
specif
exceed
one
studi
use
ict
pneumococc
urinari
antigen
test
increas
yield
etiolog
diagnosi
patient
admit
cap
patient
studi
defin
etiolog
use
convent
method
posit
pneumococc
urinari
antigen
test
immunochromatographi
assay
also
highli
accur
diagnos
pneumococc
mening
sensit
cerebrospin
fluid
sensit
urin
specif
disadvantag
urinari
antigen
test
includ
cost
lack
organ
isol
vitro
suscept
test
notabl
immunochromatographi
suitabl
evalu
therapeut
effect
posit
test
result
obtain
sever
week
month
recoveri
moreov
immunochromatograph
assay
nonspecif
pneumococc
infect
children
particularli
young
nasopharyng
carriag
pneumonia
caus
falseposit
result
one
studi
presenc
azotemia
independ
factor
associ
higher
rate
posit
test
patient
bacteremia
investig
suggest
may
increas
concentr
urin
patient
patient
revers
file
impair
renal
function
like
caus
dehydr
support
theori
effect
concentr
urin
gutierrez
colleagu
report
increas
test
sensit
urin
concentr
centrifug
studi
conduct
manufactur
found
test
abil
detect
pneumococc
antigen
decreas
serial
dilut
thu
patient
may
like
test
posit
urin
sampl
concentr
intraven
fluid
resuscit
note
pneumococc
vaccin
may
caus
falseposit
result
urin
binax
streptococcu
pneumonia
test
hour
follow
vaccin
legionella
urinari
antigen
present
urinari
antigen
use
test
north
america
detect
legionella
although
test
reliabl
detect
one
speci
legionella
pneumophila
one
serogroup
serogroup
signific
advantag
previou
standard
test
direct
fluoresc
antibodi
test
serolog
cultur
includ
rel
low
cost
rapid
perform
direct
fluoresc
antibodi
stain
requir
substanti
expertis
interpret
select
reagent
critic
cultur
select
media
detect
rare
strain
technic
demand
requir
day
accur
interpret
serolog
test
requir
comparison
acut
convalesc
specimen
relev
clinic
manag
legionella
urinari
antigen
test
sensit
greater
specif
infect
caus
l
pneumophila
serogroup
particularli
use
unit
state
europ
approxim
communityacquir
isol
serogroup
may
less
sensit
nosocomi
case
frequent
involv
serogroup
serogroup
urin
usual
posit
antigen
day
ill
continu
posit
week
recent
metaanalysi
shimada
colleagu
summar
perform
characterist
legionella
urinari
antigen
good
specif
lower
sensit
l
pneumophila
serogroup
thu
better
rule
rule
diseas
posit
urinari
antigen
test
result
appropri
clinic
set
virtual
rule
legionellosi
neg
urinari
antigen
test
result
rule
presenc
diseas
patient
confirm
legionellosi
neg
urinari
antigen
test
result
one
potenti
unintend
advers
consequ
avail
legionella
urinari
antigen
test
decreas
use
legionella
cultur
often
clinician
order
urin
antigen
test
without
submit
request
sputum
cultur
urin
antigen
test
legionella
cultur
perform
maxim
effect
especi
nonserogroup
l
pneumophila
consider
develop
naat
major
advanc
understand
respiratori
infect
pcr
relat
methodolog
revolution
field
molecular
biolog
autom
instrument
introduc
success
clinic
laboratori
set
molecularbas
test
move
research
bench
clinic
diagnost
laboratori
becom
commerci
avail
clinic
applic
method
comprehens
rapid
techniqu
may
improv
abil
quickli
effici
identifi
etiolog
organ
associ
cap
may
eventu
potenti
pointofcar
test
allow
pathogendirect
therapi
time
initi
administr
antimicrobi
agent
pcr
directli
detect
microbi
nucleic
acid
clinic
sampl
basic
step
pcr
includ
dna
extract
either
cultur
pathogen
patient
specimen
sampl
amplif
establish
target
gene
enzym
use
copi
dna
via
multipl
round
replic
result
exponenti
amplif
target
sequenc
interest
pcr
product
identifi
gel
electrophoresi
dna
sequenc
initi
pcr
method
sever
limit
includ
requir
adequ
sampl
detect
dna
presenc
pcr
inhibitor
sampl
lead
falseneg
result
contamin
lead
falseposit
result
differenti
colon
true
pathogen
eg
identif
pneumonia
respiratori
specimen
quantifi
organ
may
help
regard
equip
expens
requir
train
personnel
lack
standard
test
method
mani
hospit
laboratori
method
valid
independ
studi
method
present
approv
fda
mani
limit
address
advanc
methodolog
see
later
new
diagnost
test
pneumonia
articl
expect
resolv
technolog
improv
anticip
molecular
test
avail
near
futur
import
advanc
naat
technolog
develop
quantit
realtim
pcr
method
amplif
detect
dna
sequenc
occur
singl
tube
thu
simplifi
procedur
gel
electrophoresi
sequenc
need
reaction
perform
fluorescentlabel
dna
probe
allow
number
gene
copi
determin
increas
speed
effici
test
reduc
risk
oper
error
cross
contamin
process
perform
faster
turnaround
time
allow
result
use
promin
role
direct
patient
manag
anoth
advanc
develop
multiplex
pcr
system
multipl
dna
target
assess
one
reaction
without
increas
requir
amount
technician
time
commerci
avail
assay
measur
dozen
respiratori
pathogen
assay
may
also
abil
recogn
potenti
dual
tripl
infect
patient
sever
commerci
assay
base
autom
extract
instrument
avail
fda
approv
time
write
vari
accord
methodolog
specif
commerci
avail
realtim
pcr
includ
gene
target
beyond
scope
articl
reader
refer
review
greater
detail
present
fdaapprov
test
list
tabl
although
pcr
method
develop
sever
pneumonia
pathogen
clinic
util
test
vari
sever
advantag
pcr
test
method
compar
standard
microbiolog
cultur
method
detect
pneumonia
pathogen
box
pcr
potenti
attract
diagnost
tool
rapid
diagnosi
reli
bacteri
growth
viabil
organ
mani
pathogen
includ
chlamydophila
pneumonia
mycoplasma
pneumonia
respiratori
virus
difficult
cultur
special
growth
requir
slow
growth
time
requir
final
result
often
long
clinic
use
acut
manag
patient
realtim
pcr
shown
effect
cultur
method
detect
pathogen
pcr
specif
pathogensbacteria
streptococcu
pneumonia
common
pathogen
associ
cap
easili
detect
pcr
respiratori
specimen
pcr
techniqu
base
amplif
pneumolysin
autolysin
gene
applic
diagnosi
pneumonia
otiti
media
mening
autolysin
pneumolysin
pcr
use
sputum
shown
high
sensit
low
specif
interpret
sputum
pcr
limit
difficulti
differenti
pneumococc
colon
true
infect
hand
pleural
fluid
pcr
detect
pneumolysin
gene
sensit
specif
one
approach
may
help
resolv
problem
colon
versu
infect
quantif
target
organ
realtim
pcr
yang
colleagu
evalu
util
realtim
pneumolysin
gene
pcr
test
use
sputum
sampl
patient
admit
cap
patient
pneumonia
isol
blood
sputum
sensit
specif
use
realtim
quantit
pcr
respect
note
pcr
blood
sampl
patient
pneumonia
infect
appear
use
one
studi
compar
ict
pneumonia
urin
antigen
test
pcr
blood
patient
bacterem
pneumococc
infect
urinari
antigen
test
posit
bacterem
pneumococc
case
sensit
confid
interv
ci
wherea
pcr
posit
case
sensit
ci
p
detect
urinari
antigen
test
gave
posit
result
control
patient
refer
otherorgan
septicemia
give
specif
ci
patient
nonbacterem
cap
urinari
antigen
detect
significantli
often
patient
posit
result
pcr
protocol
p
recent
metaanalysi
conclud
current
avail
pcr
method
use
blood
sampl
diagnosi
invas
pneumococc
diseas
lack
sensit
specif
necessari
clinic
practic
date
fdaapprov
pcr
test
pneumonia
sever
commerci
avail
andor
institut
develop
naat
atyp
pathogen
howev
none
offici
fda
approv
avail
present
time
unit
state
despit
pcr
increasingli
recogn
method
choic
detect
pneumonia
c
pneumonia
pathogen
diagnosi
usual
reli
serolog
indic
previous
usual
use
clinician
acut
medic
manag
one
larg
studi
examin
use
realtim
pcr
detect
pneumonia
children
cap
found
file
pcr
detect
case
standard
diagnost
techniqu
includ
cultur
signific
pcr
result
avail
within
hoursa
major
improv
week
usual
requir
serolog
diagnosi
c
pneumonia
cultur
cell
line
tradit
consid
gold
standard
diagnosi
howev
cell
cultiv
technic
complex
associ
limit
viabil
slow
growth
restrict
special
laboratori
therefor
often
use
reason
pcr
becom
option
diagnosi
numer
assay
describ
nonfda
approv
variou
result
test
perform
signific
interlaboratori
discord
detect
rate
tuberculosi
tb
molecular
techniqu
valuabl
organ
requir
week
grow
cultur
molecular
techniqu
use
allow
appropri
isol
treatment
diseas
control
fdaapprov
pcr
assay
avail
use
patient
posit
acidfast
smear
posit
pcr
smearposit
patient
extrem
like
signal
tb
convers
neg
pcr
smearposit
patient
like
signal
infect
anoth
speci
importantli
neg
pcr
smearneg
patient
rule
tb
perhap
area
pcr
greatest
impact
pathogen
detect
respiratori
virus
gold
standard
viral
identif
convent
cell
cultur
howev
even
special
laboratori
mani
virus
readili
cultiv
thu
mani
case
viral
ill
go
undetect
exact
incid
virus
cap
remain
uncertain
pcr
offer
potenti
significantli
improv
viral
detect
mani
respiratori
virus
pcr
sensit
diagnost
approach
clinic
microbiolog
laboratori
use
revers
transcriptas
pcr
rtpcr
assay
detect
rna
virus
clinic
specimen
techniqu
sensit
detect
transcript
singl
cell
method
use
revers
transcriptas
enzym
synthes
complementari
strand
dna
rna
templat
result
complementari
dna
use
templat
pcr
assay
pcr
vital
epidemiolog
recent
influenza
pandem
commerci
avail
rapid
influenza
detect
test
ridt
found
rel
insensit
sensit
rang
depend
part
method
use
sever
recent
studi
demonstr
pcr
method
use
viral
detect
high
frequenc
viral
identif
patient
lower
respiratori
tract
infect
prospect
studi
period
adult
patient
admit
cap
etiolog
assess
use
molecular
method
pcr
virus
legionella
mycoplasma
mycobacterium
tuberculosi
pneumonia
urinari
antigen
assay
pneumonia
legionella
pneumophila
serogroup
addit
convent
studi
blood
respiratori
cultur
serolog
patient
microbi
etiolog
could
identifi
patient
howev
patient
diagnost
method
appli
pathogen
identifi
case
frequent
detect
pathogen
pneumonia
respiratori
virus
tabl
anoth
studi
use
naat
identif
respiratori
virus
adult
patient
cap
evalu
adult
patient
cap
control
subject
patient
nonpneumon
lower
respiratori
tract
infect
least
one
respiratori
viru
identifi
patient
cap
compar
control
subject
patient
nonpneumon
lower
respiratori
tract
infect
p
p
respect
tabl
interest
proport
virus
identifi
healthi
subject
zero
consid
interpret
correspond
proport
among
patient
thu
supplement
tradit
diagnost
method
new
pcrbase
techniqu
appar
virus
becom
increasingli
recogn
import
caus
cap
adult
standard
practic
except
influenza
viru
respiratori
virus
often
identifi
howev
state
recent
editori
commentari
niederman
may
chang
new
diagnost
tool
becom
wide
avail
especi
help
us
defin
etiolog
role
pathogen
encourag
develop
new
effect
antivir
therapi
good
reason
establish
etiolog
diagnosi
cap
permit
optim
antibiot
select
agent
specif
pathogen
limit
consequ
antibiot
misus
identifi
pathogen
potenti
epidemiolog
signific
legionella
tb
reduc
overus
broadspectrum
antimicrobi
hope
reduc
select
pressur
antimicrobi
resist
potenti
reduc
advers
event
thu
diagnost
test
determin
pneumonia
etiolog
essenti
role
patient
care
ensur
appropri
effect
therapi
individu
also
play
vital
role
diseas
surveil
defin
etiolog
spectrum
epidemiolog
characterist
pneumonia
case
death
develop
rapid
antigen
molecular
test
method
clinic
laboratori
longer
reliant
sole
tradit
cultur
method
detect
pathogen
clinic
specimen
rapid
etiolog
diagnos
may
achiev
howev
clinic
impact
use
molecular
test
potenti
pointofcar
diagnosi
remain
clearli
defin
studi
evalu
clinic
util
urinari
antigen
test
pneumonia
patient
cap
guchev
colleagu
prospect
assign
patient
mild
pneumonia
group
posit
urinari
antigen
test
result
treat
use
pneumococcaldirect
therapi
amoxicillin
neg
urinari
antigen
test
result
treat
clarithromycin
base
perceiv
likelihood
infect
atyp
pathogen
evalu
patient
posit
urinari
antigen
test
result
differ
clinic
outcom
group
notabl
patient
atyp
pathogen
identifi
urinari
antigenneg
arm
wherea
urinari
antigenposit
arm
indic
pneumonia
associ
atyp
pathogen
howev
sinc
atyp
pathogen
determin
serolog
method
latter
case
might
repres
primari
atyp
infect
follow
secondari
infect
pneumonia
case
probabl
clinic
manifest
infect
treat
attribut
pneumonia
may
explain
good
respons
amoxicillin
alon
investig
conclud
urinari
antigen
test
allow
administ
target
therapi
penicillinclass
antibiot
rather
broaderspectrum
agent
ad
narrowspectrum
therapi
cost
effect
allow
broadspectrum
agent
macrolid
fluoroquinolon
reserv
patient
whose
urinari
antigen
test
result
neg
potenti
cost
reduct
like
influenc
price
differ
target
broadspectrum
agent
proport
posit
test
result
also
note
time
studi
russia
littl
betalactam
macrolid
resist
pneumonia
addit
studi
perform
militari
traine
young
mean
age
year
gener
healthi
investig
suggest
addit
trial
need
clinic
set
anoth
studi
stralin
holmberg
evalu
urinari
antigen
test
hospit
patient
cap
receiv
initi
betalactam
monotherapi
median
age
year
approxim
patient
pneumonia
sever
index
class
iv
v
thu
patient
sever
ill
previous
describ
studi
thirtyeight
patient
posit
urinari
antigen
result
pneumonia
success
outcom
neg
urinari
antigen
result
success
outcom
patient
posit
pcr
sputum
test
result
atyp
pathogen
urinari
antigenposit
group
wherea
patient
posit
pcr
result
mycoplasma
spp
chlamydophila
spp
urinari
antigen
neg
group
investig
suggest
posit
urinari
antigen
test
result
support
treatment
narrowspectrum
betalactam
antibiot
addit
coverag
atyp
pathogen
need
frequent
patient
neg
test
result
recent
studi
purport
show
signific
clinic
benefit
target
treatment
base
pneumococc
urinari
antigen
period
patient
admit
cap
hospit
spain
randomli
assign
receiv
either
empir
antimicrobi
therapi
accord
intern
guidelin
receiv
target
treatment
base
urinari
antigen
test
patient
random
arm
case
cap
pneumonia
sever
class
ivv
accord
investig
target
therapi
associ
nonsignific
slightli
higher
overal
cost
primarili
cost
antigen
test
reduct
advers
event
lower
exposur
broadspectrum
antimicrobi
investig
observ
signific
clinic
differ
outcom
mortal
clinic
relaps
length
stay
hospit
fact
observ
relaps
target
arm
problem
studi
howev
investig
target
therapi
day
initi
intraven
broadspectrum
therapi
initi
thu
studi
realli
assess
potenti
pointofcar
decis
inde
investig
file
acknowledg
discuss
earlier
introduct
target
therapi
may
econom
benefit
indic
target
therapi
potenti
lead
less
resist
rapid
identif
viral
bacteri
pathogen
possibl
use
pcr
method
open
random
clinic
trial
conduct
evalu
clinic
impact
pcr
use
detect
etiolog
pathogen
patient
hospit
lower
respiratori
tract
infect
novemb
march
patient
includ
cap
exacerb
chronic
obstruct
pulmonari
diseas
respiratori
infect
patient
random
intervent
group
wherebi
result
pcr
analys
respiratori
virus
atyp
pathogen
report
hour
control
group
reli
convent
diagnost
test
although
pcr
run
report
realtim
pcr
increas
diagnost
yield
patient
compar
convent
test
primarili
increas
detect
respiratori
virus
led
cessat
antibiot
treatment
patient
overal
antibiot
use
compar
intervent
group
control
group
use
pcr
associ
increas
cost
cost
pcr
test
clinic
outcom
mortal
length
therapi
significantli
differ
point
accompani
editori
lack
chang
antibiot
use
unexpect
given
studi
design
addit
diagnos
intervent
group
viral
pathogen
mani
clinician
would
brave
enough
stop
antibacteri
agent
sole
basi
discoveri
viral
pathogen
especi
given
possibl
bacteri
copathogen
adult
furthermor
result
avail
point
initi
antimicrobi
decis
direct
therapi
might
effect
investig
indic
mimic
reallif
situat
decis
regard
treatment
chang
result
pcr
analysi
left
discret
physician
thu
standard
approach
use
inform
clinician
one
wonder
educ
process
provid
strategi
direct
therapi
might
differ
result
certainli
present
influenc
antimicrobi
stewardship
program
knowledg
earlier
diagnosi
might
better
suit
direct
pointofcar
therapi
state
investig
discuss
realtim
pcr
might
costeffect
clinician
would
less
reluct
chang
clinic
manag
basi
test
result
studi
protocolbas
morerigor
patient
manag
need
address
issu
protocol
way
fund
nation
institut
health
biolog
marker
use
attempt
distinguish
bacteri
nonbacteri
caus
pneumonia
promis
marker
procalcitonin
pct
pct
peptid
precursor
calcitonin
releas
parenchym
cell
respons
bacteri
toxin
certain
bacterialspecif
proinflammatori
mediat
ie
interleukin
il
tumor
necrosi
factora
lead
elev
serum
level
patient
bacteri
infect
pct
show
prompt
increas
upon
initi
infect
within
hour
reduc
rapidli
bacteri
infect
control
host
immun
system
antimicrobi
therapi
contrast
pct
downregul
patient
viral
infect
releas
cytokin
typic
associ
viral
infect
interferong
commonli
avail
test
kryptor
assay
lumiphor
brahm
aktiengesellschaft
hennigsdorf
germani
assay
former
prefer
higher
sensit
pct
studi
prospect
facilit
decis
whether
use
antibacteri
agent
patient
pneumonia
use
diagnosisspecif
clinic
algorithm
highli
sensit
pct
measur
shown
markedli
reduc
overus
antimicrobi
therapi
without
increas
risk
patient
random
clinic
trial
includ
patient
studi
perform
mostli
european
countri
primarili
primari
care
emerg
depart
set
trial
clinician
strongli
recommend
prescrib
antibacteri
patient
pct
level
lower
mgl
encourag
use
antibacteri
patient
level
higher
mgl
subsequ
analysi
suggest
correct
decis
sever
trial
shown
use
pct
result
help
determin
whether
antibiot
necessari
result
lower
rate
antibiot
exposur
larg
patient
random
noninferior
trial
compar
guidelinedirect
usual
care
use
rapid
pct
assay
guid
antibiot
use
group
patient
lower
respiratori
symptom
present
emerg
room
switzerland
patient
random
administr
antimicrobi
base
pct
algorithm
predefin
cutoff
rang
initi
stop
antimicrobi
pct
group
tabl
accord
standard
guidelin
control
group
use
pct
test
among
patient
acut
bronchiti
halv
percentag
patient
receiv
antibiot
therapi
usual
care
vs
pctguid
treatment
differ
rate
advers
outcom
antimicrobi
prescrib
rate
patient
cap
n
remain
appropri
high
addit
mean
durat
antimicrobi
pct
group
lower
day
control
group
day
furthermor
advers
effect
rate
antimicrobi
also
lower
pct
group
versu
control
group
ci
anoth
studi
pct
test
led
decreas
antibiot
use
primari
care
patient
present
varieti
respiratori
infect
includ
acut
bronchiti
differ
ongo
symptom
relaps
day
group
find
similar
anoth
random
noninferior
trial
patient
acut
respiratori
symptom
present
primari
care
differ
number
day
health
impair
day
compar
assign
pct
test
control
decreas
antibiot
prescript
intervent
group
studi
shown
pct
level
correl
sever
pneumonia
one
studi
pct
level
increas
time
nonsurvivor
decreas
survivor
howev
prognost
valu
pct
level
predict
mortal
advers
event
cap
remain
undefin
larg
prospect
random
clinic
trial
schuetz
colleagu
assess
perform
pct
stratifi
predefin
procalcitonin
tier
mgl
stratifi
pneumonia
sever
index
psi
confus
urea
nitrogen
respiratori
rate
blood
pressur
year
older
score
predict
allcaus
mortal
advers
event
within
day
followup
patient
cap
initi
pct
level
moder
predict
mortal
howev
pct
help
followup
predict
advers
event
therebi
improv
psi
score
accumul
evid
pct
test
use
help
identifi
patient
acut
respiratori
infect
warrant
antibacteri
therapi
practition
capabl
obtain
result
valid
test
time
manner
point
care
result
use
assess
patient
present
manifest
acut
respiratori
infect
includ
pneumonia
pctguid
initi
termin
antibiot
therapi
novel
file
approach
reduc
antibiot
overus
guid
durat
therapi
essenti
decreas
risk
side
effect
emerg
bacteri
multidrug
resist
interpret
pct
level
must
alway
account
clinic
set
knowledg
assay
characterist
pct
use
guid
diagnost
therapeut
decis
patient
cap
function
assay
sensit
cutoff
rang
need
consid
sensit
assay
one
data
deriv
kryptor
assay
result
obtain
within
hour
recommend
antimicrobi
stewardship
use
specif
pct
cutoff
see
tabl
specifi
recommend
rang
strongli
discourag
discourag
recommend
strongli
recommend
respect
util
approach
valid
multipl
random
control
trial
indic
previous
thu
use
kryptor
method
initi
continu
antimicrobi
discourag
respect
encourag
respect
see
tabl
case
antimicrobi
initi
withheld
clinic
reevalu
repeat
pct
recommend
hour
pct
increas
decis
initi
antimicrobi
appropri
time
guidelin
ensur
patient
safeti
specif
overrul
criteria
establish
pctbase
recommend
bypass
base
associ
factor
clinic
judgment
see
tabl
past
decad
diagnost
test
detect
respiratori
pathogen
rapidli
evolv
immunochromatographicbas
urinari
antigen
test
rapid
simpletoperform
assay
easili
develop
pointofcar
patient
test
develop
depend
defin
new
antigen
readili
detect
molecular
diagnost
techniqu
becom
increasingli
popular
clinic
microbiolog
laboratori
mani
combin
sensit
specifi
rapid
turnaround
time
allow
time
patient
care
develop
method
clinic
microbiolog
laboratori
longer
reliant
sole
convent
cultur
method
detect
pathogen
molecular
method
creat
new
opportun
clinic
microbiolog
laboratori
affect
patient
care
area
initi
diagnosi
therapi
time
method
becom
autom
potenti
clinic
util
increas
addit
provid
excel
new
tool
diagnosi
molecular
test
also
serv
use
role
infect
control
public
health
critic
issu
regard
clinic
util
molecular
test
turnaround
time
abl
use
test
pointofcar
diagnosi
optim
result
within
hour
howev
even
turnaround
time
longer
still
use
appropri
antimicrobi
therapi
allow
earlier
pathogendirect
discontinu
therapi
moreov
question
avail
smaller
commun
hospit
abl
ration
ad
cost
equip
personnel
run
test
time
manner
addit
issu
laboratori
reimburs
need
address
current
reimburs
cpt
code
adequ
cover
cost
mani
molecular
test
cours
test
result
result
downstream
lower
total
cost
care
shorten
ill
length
stay
cost
justifi
molecular
test
becom
avail
studi
necessari
evalu
real
clinic
valu
use
test
result
real
improv
patient
care
outcom
cost
effect
reduc
advers
event
antimicrobi
resist
result
studi
avail
controversi
concern
target
therapi
empir
therapi
remain
final
mani
studi
mostli
europ
show
pct
level
help
distinguish
bacteri
viral
pneumonia
reduc
antibacteri
use
predict
sever
base
magnitud
result
may
predict
surviv
molecular
test
time
avail
result
determin
great
extent
util
pointofcar
test
ongo
studi
substanti
util
pct
